Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

Report Published: "Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Review, H2 2013"


Print article Print article
2014-01-27 11:02:51 - Recently published research from Global Markets Direct, "Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Review, H2 2013", is now available at Fast Market Research

Global Markets Direct's, 'Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome). Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Full Report Details at
-

www.fastmr.com/prod/769163_mucopolysaccharidosis_ii_mps_ii_hunte ..

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome).
* A review of the Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to Get this Report

* Identify and understand important and diverse types of therapeutics under development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome).
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned in this Report: Lentigen Corporation, Shire Plc, Green Cross Corporation, JCR Pharmaceuticals Co., Ltd., ArmaGen Technologies, Inc.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Overview
Therapeutics Development
Pipeline Products for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Overview
Pipeline Products for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Comparative Analysis
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Therapeutics under Development by Companies
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Products under Development by Companies
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Companies Involved in Therapeutics Development
Lentigen Corporation
Shire Plc
Green Cross Corporation
JCR Pharmaceuticals Co., Ltd.
ArmaGen Technologies, Inc.
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Assessment by Therapeutic Class
Drug Profiles
idursulfase - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JR-032 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AGT-182 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LG-1041 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
idursulfase - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Recent Pipeline Updates
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Dormant Projects
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Product Development Milestones
Featured News & Press Releases
Jul 18, 2013: ARMAGEN Receives US Orphan Designation For Lead Product AGT-182
Apr 08, 2013: Green Cross Announces Publication Of Clinical Trial Paper On Hunter Syndrome Drug Hunterase In International Scientific Press
Feb 18, 2013: Green Cross Receives FDA Orphan Drug Designation For Hunterase For Treatment Of Hunter Syndrome

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=769163&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.


Author:
Bill Thompson
e-mail
Web: www.fastmr.com
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com